Navigation Links
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/30/2009

disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments we may receive; the amount of earn out payments we may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under our license agreement for additional indications; the potential benefits of our existing license and development agreements; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

                                  BioSpecifics Technologies Corp.
                              Consolidated Statements of Operations

                                Three months ended         Twelve months ended
                                    December 31                  December 31
                                    (Unaudited)                  (Audited)
                                    -----------                  -----------
                                 2008         2007           2008         2007
                                 ----         ----           ----         ----
    Revenues:
      Net sales                 7,502      $12,297        $37,343      $34,357
      Royalties               508,099       16,361        510,127       16,361
      Licensing and
       sublicensing fees    6,641,281      289,279      7,440,125    1,157,116
      Consulting fees          70,000       96,500        424,185      306,500
                               ------       ------        -------      -------
    Total re
'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
2. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
3. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
4. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
5. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
6. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
9. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
10. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
11. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... MENLO PARK, Calif. , April 30, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... operating results on Thursday, May 7, 2015 after the ... host a conference call and webcast on Thursday, May ... Pacific to discuss the results and recent corporate developments. ...
(Date:4/30/2015)... , April 30, 2015 WuXi PharmaTech (Cayman) ... a leading global contract R&D services provider, today announced ... non-binding proposal letter, dated April 29, 2015, from a ... (the "Chairman"), founder, chairman and chief executive officer ... ("ABG") that proposes a transaction (the "Transaction") involving the ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/30/2015)... 30, 2015 Clinovo Staffing Solutions ... Annual Conference held in Orlando, FL on May ... along with Leslie Kolman, Manager of Staffing Solutions, will ... news at Booth #17. , “We are excited ... this year”, Says Trisha Heredia, Senior Director of Staffing ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3WuXi PharmaTech Announces Receipt of Proposal 2WuXi PharmaTech Announces Receipt of Proposal 3WuXi PharmaTech Announces Receipt of Proposal 4WuXi PharmaTech Announces Receipt of Proposal 5WuXi PharmaTech Announces Receipt of Proposal 6Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3
... ImmusanT, Inc., a biotechnology company developing an immunotherapeutic ... disease, reported positive results from a Phase 1 ... Nexvax2® in patients with celiac disease. ImmusanT Chief ... results from the Nexvax2 Phase 1 study and ...
... Medical Inc. (OTCBB: ONCS), a therapeutic oncology company ... cancers with unmet medical needs, announced today the ... profiled in Medical Device Daily, the news source ... relied on by thousands of industry insiders every ...
... 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... highlights for the quarter ended March 31, 2011. For the ... million compared to net revenues of $45.5 million in the ... quarter of 2011 was $(11.8) million, or $(0.25) per share, ...
Cached Biology Technology:ImmusanT Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease 2ImmusanT Reports Positive Results from Nexvax2 Phase 1 Study in Celiac Disease 3OncoSec Medical Featured in Medical Device Daily 2Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 2Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 3Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 4Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 5Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 6Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 7Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights 8
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the ... Business Report" report to their offering. This report ... Thousands by the following Segments: Face Biometrics, and Voice Biometrics. The ... , Japan , Europe ... & Africa , and Latin ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... campaign on CNBC television starting March 30 th . ... airing in New York markets. ... "We are excited about our new ad campaign following the ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... firefighters, police officers and ambulance workers faced a terrifying ... battled to save people from the collapsing Twin Towers, ... people as they could in an area which contained ... harder was the problem of poor communications: frightened workers ...
... MADISON, WI, NOVEMBER 25, 2009 Soil is the ... meet. Despite that, many students see soil as "just ... more. Soil science educators are challenged with the task ... importance of soil in the environment. A ...
... State University assistant professors recently received funding from ... beneficial to understanding the environment. The three grants ... the Department of Biological Sciences, was awarded grants ... first project, titled "Assembling Litter Decomposer Communities and ...
Cached Biology News:Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Kent State University professors focus research on the environment with grants totaling $890,000 2
Amino-acids and Derivatives Rabbit Anti-conjugated L-isoleucine Polyclonal Antibody...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
PPIF Antibody...
Rabbit polyclonal to FLIP ( Abpromise for all tested applications). entrezGeneID: 8837 SwissProtID: O15519...
Biology Products: